Anne C. Whitaker was appointed Director of Alkermes plc. As of November 6, 2026, Alkermes plc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from August 3, 2026 to September 16, 2026, naming 1 appointment (Form 8-K, September 16, 2026).
Alkermes plc. named a new Director on Sep 16. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Alkermes plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Alkermes plc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-08-03 to 2026-09-16. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Alkermes plc. files it.
Also on the record for Alkermes plc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 2.8% of the class | 5%+ stakes | Source |
| April 28, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.21% of the class | 5%+ stakes | Source |
| April 28, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.8% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Baker Bros. Advisors LP | 6.1% of the class | 5%+ stakes | Source |
| February 11, 2026 | Acquired Avadel | $1.50B | Acquisition | Source |
| November 10, 2025 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.2% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 6.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Alkermes plc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Alkermes plc. and the records around it.
Alkermes plc. elsewhere on the record
- Acquisition Feb 2026
- Who owns it
Companies that share a holder
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
- T. Rowe Price Associates, Inc. also filed stake reports on 191 other companies: PACIFIC BIOSCIENCES OF CALIF (Nov 2026), APARTMENT INVT & MGMT CO -A (Oct 2026), BETA BIONICS INC (Oct 2026)
- STATE STREET CORPORATION also filed stake reports on 343 other companies: TRADE DESK INC/THE (Oct 2026), CENTRUS ENERGY CORP (Sep 2026), ACADIA PHARMACEUTICALS INC (Aug 2026)
Watch Alkermes plc.
Get an email when Alkermes plc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Alkermes plc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Alkermes plc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Alkermes plc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-16 | In | Director | 8-K, 2026-09-16 | ||
| 2026-08-03 | Reported | not named in the filing | 8-K/A, 2026-08-03 |
Who leads Alkermes plc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Anne C. Whitaker, appointed (filed 2026-09-16).
New leaders reset buying decisions — get the Full Report on Alkermes plc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Alkermes plc., with the record behind each one.
Find candidates like Director at Alkermes plc.Every change, in the filing's words
Appointed: Anne C. Whitaker, Director
On September 14, 2026, the board of directors (the "Board") of Alkermes plc (the "Company") increased the size of the Board from ten (10) to eleven (11) directors and appointed Anne C. Whitaker to the Board, effective immediately, with an initial term expiring at the Company's 2027 annual general meeting of shareholders.
- For her service on the Board, Ms. Whitaker will be entitled to receive an annual cash retainer and annual equity grant, both of which will be on the terms, and in the amounts, as determined in accordance with the processes described in the "Director Compensation" section of the Company's definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on April 6, 2026.
- In addition, in connection with her appointment to the Board, Ms. Whitaker will be granted an initial new director equity award with an aggregate target value of $600,000, consisting of 50% stock options and 50% restricted stock unit awards, which will vest and, as applicable, become exercisable in three equal annual installments commencing on the first anniversary of the grant date, subject to Ms. Whitaker's continuous service.
- The new director equity award is expected to be granted to Ms. Whitaker in October 2026, on the Company's monthly new hire employee grant date.
- The exercise price per share of the stock options will be equal to the closing price of the Company's ordinary shares on the date of grant, as reported on the Nasdaq Global Select Market.
Reported
In his new role, Mr. Jackson will cease serving as the Company's Chief Operating Officer.
- As previously disclosed, on February 24, 2026, the Board appointed Mr. Jackson to serve as the Company's CEO, effective August 1, 2026.
- On July 28, 2026, the Board took action to expand Mr. Jackson's responsibilities and, commensurate with such expansion, to also appoint Mr. Jackson as President of the Company, effective August 1, 2026, and to approve Mr. Jackson's compensation arrangements for his role as President and CEO, in each case effective August 1, 2026.
- Also on July 28, 2026, the Board approved an increase to the size of the Board from nine to ten directors and appointed Mr. Jackson as a member of the Board for a term expiring at the Company's 2027 annual general meeting of shareholders and as a member of the Financial Operating Committee of the Board, in each case effective August 1, 2026.
- Mr. Jackson will not receive any compensation for his service on the Board or the Financial Operating Committee of the Board.
- In connection with his appointment as President and CEO, effective August 1, 2026, Mr. Jackson's annual base salary will be increased to $900,000, and his target annual cash performance award under the Company's reporting officer performance pay plan will be increased to 100% of his new base salary, with a target annual cash performance award pay range of 0% to 200% of his new base salary.
Tools for this story
Each opens in a new tab, filled in for Alkermes plc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.